Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 24 April 2019


Medicinal product no longer authorised

Short term treatment of the following superficial skin infections in adults, adolescents, infants and children (aged from nine months):
• Impetigo.
• Infected small lacerations, abrasions, or sutured wounds.

See sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus.

Consideration should be given to official guidance on the appropriate use of antibacterial medicinal products.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000757
Orphan designation No
Date First Approved 24-05-2007
Type Medicinal product subject to medical prescription
Marketing authorisation holder Glaxo Group Ltd.